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Introduction
Erythropoiesis is an essential process that takes place in 
the bone marrow and is characterized by the proliferation and 
maturation of cells committed to the erythroid lineage. The 
glycoprotein erythropoietin (Epo), predominantly secreted 
by the adult kidney, is regarded as the major promoter of 
erythropoiesis, as it stimulates proliferation and prevents the 
apoptotic death of early (BFU-E, Burst-Forming Units-Erythroid) 
and late (CFU-E, Colony-Forming Units-Erythroid) erythroid 
progenitors, thus allowing their further differentiation to the 
erythroblast and reticulocyte stages, and finally to erythrocytes.
More recently, research aimed at understanding the basic 
mechanisms of its biological effect has revealed a pleiotropic 
cytoprotective activity of Epo beyond the regulation of 
erythropoiesis. These findings have placed Epo as a compound of 
therapeutical interest in neurodegenerative and cardiovascular 
diseases, apart from the treatment of anemia.
Experimental evidence of Epo activity in tissues outside 
the bone marrow has suggested the participation of different 
membrane receptors for the cytokine. In this regard, the 
association between EpoR and the β-common subunit shared 
by the IL-3, IL-5 and GM-CSF receptors (βcR or CD131) [1], as 
well as experimental evidence collected from βcR knockout mice 
 
support the hypothesis of a cytoprotective effect of Epo mediated 
by the EpoR- βcR heteroreceptor [2].
With the aim of broadening the therapeutic spectrum of 
rhuEPO, the ability of the cytokine to treat anemia of chronic 
disease is not the only point to be considered, but also its 
protective activity against inflammation andapoptotic stimuli. 
In these situations, the erythropoietic activity of Epo could 
be detrimental for non-anemic patients, as it induces an 
unnecessary and potentially harmful increase in erythrocyte 
mass. This has prompted researchers to find derivatives of Epo 
incapable of erythropoiesis but with a cytoprotective action. One 
such compound is carbamylated erythropoietin (cEpo), obtained 
by incubation of rHuEpo with potassium cyanide. This reaction 
yields a structurally modified cytokine in which one carbamyl 
group is irreversibly coupled to each of the lysine residues in 
the Epo molecule, potentially causing functional alterations. 
In vivo, the isocyanate generated by the dissociation of urea is 
responsible for the carbamylation of different proteins, which 
may play a role in the development of various diseases. In this 
regard, the carbamylation of endogenous Epo could be involved 
in chronic renal failure patients showing resistance to treatment 
with recombinant human Epo.
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Moreover, carbamylation renders erythropoietin unable 
to bind the classical EpoR2 receptor [3,4]. Competence assays 
performed by our group showed that an excess of cEpo inhibited 
the ability of GM-CSF to stimulate proliferation of TF-1 cells [5], 
thus suggesting that cEpo binds to the β-common subunit and 
could utilize the EpoR-βcR heteroreceptor.
After cEpo administration, rats displayed no alterations in 
their hematological parameters, supporting a loss of biological 
activity after carbamylation [6]. Comparative studies between 
the native and the carbamylated Epo have demonstrated an 
inability of the latter to stimulate the formation of hematopoietic 
colonies from CD34+ bone marrow cells [7], and to promote 
erythroid proliferation and survival in mice bone marrow-
derived CFU-E, as well as in cultures of the UT-7 and TF-1 human 
erythroid cell lines [5].
The development of cEpo paved the way for new 
pharmacological studies in non-hematopoietic tissues, with 
neuroprotection being one of the most important endpoints. 
In mice, cEpo was found to prevent tissue damage due to 
spinal hemisection [8], hipoxia [9], experimental autoimmune 
encephalomyelitis [10] and focal brain ischemia [11]. Results 
obtained by our group confirmed that the modification of Epo by 
carbamylation does not affect its neuroprotective action on SH-
SY5Y cells [5]. By carring out inhibition and competence assays, 
we also observed that cEpo requires both the EpoR and the βcR 
subunit to prevent apoptosis in neuronal cells. In recent years, 
the neuroprotective action of the carbamylated erythropoietin 
has continued to attract attention, as newly reported research 
shows experimental results about the cellular and molecular 
mechanisms involved in the process of neuroprotection of cEpo 
[12,13].
Apart from the nervous system, cytoprotection has also 
been tested in the cardiovascular system. In this regard, cEpo 
was shown to prevent myocardium damage in a mouse model 
of ischemia-reperfusion injury [14] as well as epilepsy-derived 
myocardiocyte apoptosis [15]. However, the effect of cEpo on 
endothelial cells has not yet been deeply explored.
Unlike Epo, cEpo was found unable to promote proliferation 
of mature endothelial cells [7,16]. Similarly, carbamylation 
impaired the promigratory action of the native cytokine in 
cultures of the human EA.hy926 endothelial cell line. An 
investigation of the membrane receptors involved in such 
effect showed that Epo does not require the βcR subunit to 
promote endothelial cell migration [16], thus suggesting that 
Epo may utilize similar transduction pathways in erythroid 
and endothelial cells. However, in competence assays the 
promigratory effect of Epo on endothelial cells was impaired 
by an excess of cEpo [17]. Given that the same tendency was 
observed in the erythroid lineage, where a high concentration 
of cEpo blunted the effect of the native cytokine on mice CFU-E 
cells and on the human UT-7 and TF-1 cell lines [5], it is possible 
that upon cEpo exposure, the formation of the heteroreceptor 
reduces the availability of the EpoR subunit, thus interfering 
with the activity of Epo.
The differential effects of Epo and cEpo in erythroid cells 
have prompted research to clarify its underlying mechanisms. 
Cytokine receptors are generally devoided of kinase activity. 
Instead, they are associated to kinases such as Jak2, which 
activate by transphosphorylation and become able to 
phosphorylate other substrates. Although in cultures of erythroid 
UT-7 and TF-1 cells cEpo induced Jak2 phosphorylation, a 
research work by our group demonstrated for the first time 
that cEpo was unable to maintain Akt and the transcription 
factor FOXO3a phosphorylated for the same period of time as 
Epo [5]. Dephosphorylation of FOXO3a and its subsequent 
translocation to the nucleus stimulates the expression of the cell 
cycle inhibitory protein p27kip1. Consistently with the inability 
of cEpo to stimulate proliferation, p27kip1 was found increased 
in cell cultures exposed to the modified cytokine. cEpo was also 
found to induce Jak2 and Akt phosphorylation in endothelial 
progenitors [18] and in mature endothelial cells [17].
Given that the differential effect of Epo and cEpo on cell 
proliferation could be associated to the silencing of transduction 
pathways by an increase in the dephosphorylation rate, we also 
analyzed the expression and activity of the protein tyrosine 
phosphatase 1B (PTP1B), involved in the inactivation of Epo 
signalling. cEpo induced PTP1B to a significantly higher level 
than Epo. Moreover, co-localization of PTP1B and βcR supports 
the conclusion that the phosphatase inactivates the signal 
triggered by cEpo much faster than that of Epo, thus interrupting 
pathways of survival and proliferation [19]. As observed in 
erythroid cells, cEpo enhanced PTP1B expression in endothelial 
cells, and the inhibition of this phosphatase allowed this 
modified erythropoietin to overcome its inability to promote 
endothelial cell migration [16]. These results may explain, at 
least in part, the differential effects of Epo and cEpo on erythroid 
and endothelial cells.
Conclusion
Following carbamylation, cEpo maintains its neuroprotective 
ability based on its antiapoptotic and antioxidant properties, 
while it is unable to stimulate erythropoiesis. This makes 
cEpo a promising agent to prevent an unnecessary increase 
in erythroid mass in non-anemic patients under treatment 
for neurodegenerative diseases. However, precise focus upon 
interference of high doses of cEpo with Epo is required to 
elucidate the benefits and risks of future therapeutic strategies.
This revision provides recent information regarding the 
signalling pathways involved in cell mechanisms induced by Epo 
and cEpo that could predict their differential effects on erythroid 
and endothelial cells as well as open interesting research 
areas concerning the potential role of tyrosine-phosphatases 
in controlling growth factor functions. Further research is 
required to determine the effectiveness of erythropoietin and 
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its derivatives on different tissues with the aim of setting the 
foundations for the development of conclusive clinical trials.
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